Neogen Corporation Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Neogen Corporation (NEOG) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $17.47 per share for the 12-month period ending 2025-05-31, per its 10-K filed 2025-07-30.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2025-07-30
- Neogen Corporation share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2022-08-31 was $37.60.
- Neogen Corporation share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2025 was $17.47, a 12.56% decline from fiscal 2024.
- Neogen Corporation share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2024 was $19.98, a 12.41% decline from fiscal 2023.
- Neogen Corporation share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2023 was $22.81, a 38.02% decline from fiscal 2022.
- Neogen Corporation share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2022 was $36.80, a 7.57% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-05-31 | $17.47 10-K · filed 2025-07-30 | |||
| 2024-05-31 | $19.98 10-K · filed 2025-07-30 | |||
| 2023-05-31 | $22.81 10-K · filed 2024-07-30 | |||
| 2022-08-31 | $37.60 10-Q · filed 2022-09-30 | |||
| 2022-05-31 | $36.80 10-K · filed 2023-08-15 | |||
| 2022-02-28 | $35.61 10-Q · filed 2022-04-01 | |||
| 2021-11-30 | $34.49 10-Q · filed 2021-12-30 | |||
| 2021-05-31 | $34.21 10-K · filed 2022-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |